Jakob, we'd really like to know -

Quote

anonymous

Guest
What have you done other than:
- remove JQSL for an obvious legal issue
- demote, though protect, CLEE to a PA position that was never posted to be an ET position. But yet you were either afraid of the backlash or needed the diversity on ET, knowing you'd list JQSL and would lose EDDW. Kudos though for removing her so quickly. Good decision making on that one.
- put a Prior Authorization on Saxenda for employees. As everyone from the market access team to each rep, we espouse patient centricity and work everyday to sell why payers and employers should NOT have access restrictions in place, yet you and your svelte Danish colleagues have decided to 'balk the walk': Say one thing, then do another. Tell employers and payers how important access to Saxenda is, then restrict your own employees access.

I guess you and Simon know better. That's why NVO shares are out performing the market so well.

Oh, what ? My bad, I forgot, NVO shares are down - pushing towards a 50% drop while the markets rocks.

You must have some secret that we're just waiting to hear.

So really, let's list what positive impacts Jakob and the ET have had so far this year.

Start now.
 




The Saxenda thing is probably the one that makes the least bit of sense. Restricting it while reps talk to providers about how our AEs are working to get better access to Saxenda and we can't even get it without the doctor having to document. This company is going down the toilet. Not sure what business plan Jakob gave the board to get the job, I was sure he had better sense then to keep the same old ELT Team in place who couldn't figure out a plan before. None of this adds up!
 




it does all add up

Over the next two years, the salesforce will be crushed for "not delivering".
Those that stay, will live a shitty Novo existence.

It's the model for a ZS associates
5 year cleansing.
 




anonymous said:
What have you done other than:
- remove JQSL for an obvious legal issue
- demote, though protect, CLEE to a PA position that was never posted to be an ET position. But yet you were either afraid of the backlash or needed the diversity on ET, knowing you'd list JQSL and would lose EDDW. Kudos though for removing her so quickly. Good decision making on that one.
- put a Prior Authorization on Saxenda for employees. As everyone from the market access team to each rep, we espouse patient centricity and work everyday to sell why payers and employers should NOT have access restrictions in place, yet you and your svelte Danish colleagues have decided to 'balk the walk': Say one thing, then do another. Tell employers and payers how important access to Saxenda is, then restrict your own employees access.

I guess you and Simon know better. That's why NVO shares are out performing the market so well.

Oh, what ? My bad, I forgot, NVO shares are down - pushing towards a 50% drop while the markets rocks.

You must have some secret that we're just waiting to hear.

So really, let's list what positive impacts Jakob and the ET have had so far this year.

Start now.
Click to expand...
Has anyone else noticed that a couple VPs on the market access side were promoted in this fiasco? I'm sure that was needed to help right the ship.

This place sucks.
 




anonymous said:
Has anyone else noticed that a couple VPs on the market access side were promoted in this fiasco? I'm sure that was needed to help right the ship.

This place sucks.
Click to expand...

This place is no different than any other place. I guess that's the real problem. It used to be different, and we prided ourselves on being different. Now, we're just another run-of-the-mill pharma company happily cutting their way to growth, with the focus on keeping the investors happy at the expense of the employees. And, right now, we're not even keeping the investors happy.

I've been a rah-rah Novo fan for many years, but not anymore. Too many bad decisions made at the top that get taken out on the hide of those at the bottom. Tresiba forecast too high - salesforce sucks for not hitting it. Too much money given away in market access contracts - salesforce sucks for not executing on wins. DCA expansion debacle - cut tenured people and leave 1/2 the DCA team still in place and still sucking hind tit. Years of bragging about Xultophy and its potential impact - limited patient base, no longer a 'priority brand', isn't going to help our financial performance. The list goes on and on of how bad these strategic decisions are and how the top brass has decided to take it out on the tactical performance - sell better, pull thru CVS, more training, variability piece, blah blah blah. This place just makes me sad nowadays. It's time for me to go.
 




I have been with other big pharma companies this place seems to be getting even worse than them. Poor leadership, here Jakob had the opportunity to put his own people in place and didn't even clean house. Just cut sales force people no DMs. Just poor planning and ineffective territories that have 3 and 4 reps assigned to them. This place is still operating like everything is guns and roses. No good planning to get the stock up. Not sure what Jakob told the board to get the job. At this time my vote is on Jakob, Andy, Lynn and all these uselessness AEs.
 




Top Bottom
Back
Quote